A Phase Lb Dose Escalation Trial Of Isatuximab (Sar650984, Anti-Cd38 Mab) Plus Lenalidomide And Dexamethasone (Len/Dex) In Relapsed/Refractory Multiple Myeloma (Rrmm): Interim Results From Two New Dose Cohorts.
JOURNAL OF CLINICAL ONCOLOGY(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要